Brook Jackson is a whistleblower suing Pfizer and her former employer, Ventavia Research Group, in Federal court under the False Claims Act for fraud she witnessed during the Pfizer COVID-19 mRNA clinical trials in September 2020.
The heart of Jackson’s lawsuit centers on claims of fraud in Pfizer’s clinical trials and manufacturing processes. Evidence suggests the vaccine, particularly the scaled-up Process 2, was inadequately tested, with only a couple of hundred people evaluated compared to the 40,000 in Process 1 trials. This shift introduced significant risks, including DNA contamination from E. coli and the inclusion of SV40, a segment known to promote rapid cell growth, potentially linked to increased cancer rates. These allegations point to a product that not only failed to meet contractual obligations but also posed serious health risks, with approximately 20% of recipients experiencing adverse effects, 5% of which were severe, ranging from cancers to fatalities.
The legal battle has been fraught with obstacles. The Biden administration intervened, arguing that the case was contrary to public health policy, leading to its dismissal by a federal judge. This decision, lacking clear justification, is now under appeal in the Fifth Circuit Court of Appeals. The Department of Justice’s (DOJ) standards for dismissing such cases were not met, raising questions about political motivations. The delay in scheduling oral arguments further complicates the pursuit of justice, leaving Jackson and her legal team in a “weird vacuum” of media silence. Mainstream outlets like The New York Times and The Washington Post have largely ignored the case, underscoring the challenges whistleblowers face in gaining public attention.
The implications of this case are profound. A successful appeal could strip Pfizer of its legal immunities, exposing the company to liabilities potentially in the trillions, which could lead to its bankruptcy. Such an outcome would send a powerful message about corporate accountability and the necessity of rigorous oversight in pharmaceutical development. The case also highlights systemic issues with regulatory agencies like the FDA, which have been criticized for inadequate scrutiny of Pfizer’s submissions. The intentional inclusion of SV40, hidden from regulators, further erodes trust in these institutions, suggesting a prioritization of corporate interests over public safety.Jackson’s case is not just about one company; it reflects a broader struggle against the erosion of individual liberties under the guise of public health.
Historical precedents like Buck v. Bell and the eugenics movement reveal a troubling pattern of prioritizing collective goals over personal rights, a trend that continues with vaccine mandates for healthcare workers. These mandates, often enforced without regard for individual choice, echo past injustices and underscore the need for reform, possibly through legislative changes to Title VII to protect bodily autonomy.
Ultimately, Jackson’s fight is a call to action for the American public to demand transparency and accountability. As her attorney Warner Mendenhall emphasizes, relying solely on government figures like Robert F. Kennedy Jr. or political leaders is insufficient. The public must engage, research, and amplify these issues to hold corporations like Pfizer accountable. By supporting whistleblowers like Jackson, society can challenge the unchecked power of pharmaceutical giants and ensure that public health serves the people, not corporate profits. The road to justice is long, but the pursuit of truth remains essential for a free and informed society.
Learn more about Brook Jackson’s case and follow her on X @iambrookjackson. Warner Mendenhall is the founder of Freedom Counsel. Follow him on X @mendenhallfirm.
